Grifols, SA
GRF
ISIN ES0171996087 / Valor 30689493
Grifols, SA
UMushroom community rating:
About company
Grifols, SA is a leading global healthcare company that specializes in plasma-derived medicines, biopharmaceuticals, and solutions in transfusion medicine. The company is known for its innovative products and services that enable millions of patients around the world to lead more productive lives. Grifols is also involved in the agglutination technique to determine blood groups and transfusion compatibility studies, using gel as a reagent in columns on cards. Additionally, the company is engaged in the preparation of intravenous medicines for fluid therapy, contributing to the healthcare industry with its expertise and commitment to improving patient outcomes.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (22.11.2025):
Grifols, SA — Q3 2025: The company reported Q3 revenues of EUR 1,865 million (+9.1% constant currency), bringing nine‑month revenues to EUR 5,542 million (+7.7% cc). Adjusted EBITDA for Q3 was EUR 482 million (+8.8% cc) with a 25.8% margin (YTD adjusted EBITDA EUR 1,358 million; 24.5% margin). Group profit in Q3 was EUR 127 million (EUR 304 million YTD, +245% YoY). Free cash flow pre‑M&A pre‑dividend was EUR 203 million in Q3 and EUR 188 million YTD (EUR +257 million YoY improvement). Leverage fell to 4.2x (from 5.1x prior year) and liquidity stood at EUR 1,475 million; FX headwind vs guidance FX is ~EUR 70 million for full‑year Adjusted EBITDA.
Revenue and growth
Q3 revenue EUR 1,865m (+9.1% cc); YTD EUR 5,542m (+7.7% cc). Growth was led by Biopharma, notably immunoglobulins (IG) +14.4% cc YTD and subcutaneous IG >60% cc YTD; albumin down 3.9% cc YTD due to pricing adjustments in China.
Profitability & margins
Adjusted EBITDA Q3 EUR 482m (+8.8% cc) with a 25.8% margin; YTD adjusted EBITDA EUR 1,358m (24.5% margin). Group profit Q3 EUR 127m and EUR 304m YTD (+245% YoY), reflecting margin expansion and lower financial costs.
Cash flow & deleveraging
Free cash flow pre‑M&A pre‑dividend Q3 EUR 203m (YTD EUR 188m), improving EUR 257m YoY driven by higher EBITDA, lower CAPEX and reduced cash interest. Leverage improved to 4.2x (from 5.1x) and liquidity increased to EUR 1,475m.
Business drivers
Biopharma is the main growth engine (IG franchise and subcutaneous formulation strong). Alpha‑1 and Specialty proteins showed solid progress; albumin declines were managed through local pricing partnerships in China.
Diagnostics & regulatory
Diagnostics revenue YTD EUR 479m (+1.4% cc), supported by Blood Typing Solutions and Molecular Donor Screening. FDA approved manufacturing of Gel Cards and reagent Red Blood Cells at the San Diego facility.
Guidance & FX impact
At Guidance FX rates (EUR/USD 1.04), management maintained Adjusted EBITDA guidance but improved revenue and FCF pre‑M&A pre‑dividend guidance. Current FX is estimated to be a ~EUR 70m headwind to full‑year Adjusted EBITDA and broadly neutral for group profit, free cash flow and leverage. Summarized from source with an LLMView Source
Key figures
Performance
Volatility
5421 M
Market cap (USD)
3,036,494
Daily traded volume (Shares)
9.186 / 9.04
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
